Cargando…
Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre
BACKGROUND: Patients with hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT), especially type Vp-4, usually have a poor prognosis. However, the vast majority of Phase III clinical trials exclude this population based on the inclusion criteria. Lenvatinib plus a PD-1 inhibitor has...
Autores principales: | Li, Guangxin, Zhao, Ying, Li, Keren, Yang, Shizhong, Xiang, Canhong, Song, Jiyong, Yang, Yanmei, Li, Gong, Dong, Jiahong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642359/ https://www.ncbi.nlm.nih.gov/pubmed/37965075 http://dx.doi.org/10.2147/JHC.S432542 |
Ejemplares similares
-
Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial
por: Li, Guangxin, et al.
Publicado: (2022) -
Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial
por: Hu, Yue, et al.
Publicado: (2020) -
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021) -
Design and Uncertainty Analysis for a PVTt Gas Flow Standard
por: Wright, John D., et al.
Publicado: (2003) -
Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus
Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular
Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)